ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

OPCT-001

A development code. Also written as “OpCT-001”.

Its studies are mostly in Usher Syndromes, led by Bayer.

Furthest: phase 2, since Jan 17, 20251 company-led study, 1 open or runningNext primary completion: Oct 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer11 open or runningphase 2since Jan 17, 2025Jan 17, 2025Oct 2029phase 2 · NCT06789445

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 17, 2025First study: phase 2 study in Retinitis PigmentosaFirst studyNCT06789445 · 54 planned · United States

Ahead

  1. Oct 2029Primary completion: phase 2 study in Retinitis PigmentosaNCT06789445

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06789445Retinitis Pigmentosa · United States2RecruitingOct 202954

How it is read

Names in the registry

  • “OpCT-001”, 2 entries

Codes read as this program: OPCT001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.